	US 12,187,795 B2
	Anti-LAG-3 antibodies and methods of use thereof
Nicholas Stuart Wilson, San Carlos, CA (US); David Adam Savitsky, Boxford, MA (US); Shawn Michael Jennings, Acton, MA (US); Marc van Dijk, Bosch en Duin (NL); and Cornelia Anne Mundt, Lörrach (DE)
Assigned to AGENUS INC., Lexington, MA (US)
Filed by Agenus Inc., Lexington, MA (US)
Filed on Oct. 23, 2020, as Appl. No. 17/078,602.
Application 17/078,602 is a division of application No. 15/730,249, filed on Oct. 11, 2017, granted, now 10,844,119.
Claims priority of provisional application 62/420,280, filed on Nov. 10, 2016.
Claims priority of provisional application 62/406,766, filed on Oct. 11, 2016.
Prior Publication US 2021/0054074 A1, Feb. 25, 2021
Int. Cl. A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 47/6873 (2017.08); A61P 35/00 (2018.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01)]

18 Claims

1. An isolated polynucleotide encoding an antibody comprising complementarity determining regions CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3,

wherein CDRH1, CDRH2, and CDRH3 are found in a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 65; and CDRL1, CDRL2 and CDRL3 are found in a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 73.